Histamine H1-receptor antagonists inhibit nuclear factor-kappaB and activator protein-1 activities via H1-receptor-dependent and -independent mechanisms

被引:33
作者
Roumestan, C. [1 ]
Henriquet, C. [1 ]
Gougat, C. [1 ]
Michel, A. [2 ]
Bichon, F. [2 ]
Portet, K. [2 ]
Jaffuel, D. [3 ]
Mathieu, M. [1 ]
机构
[1] INSERM, U454, Montpellier, France
[2] Univ Montpellier, Fac Pharm, Lab Pharmacol & Physiopathol Expt, F-34059 Montpellier, France
[3] Ctr Med Specialise Pneumol, F-34500 Beziers, France
关键词
antagonists; histamine H1-receptor; 5-lipoxygenase; NF-kappa B; RANTES; transcription factor AP-1;
D O I
10.1111/j.1365-2222.2008.02990.x
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background Histamine H1-receptor antagonists are used to relieve the symptoms of an immediate allergic reaction. They have additional anti-inflammatory effects that could result from an inhibition of the transcription factors activator protein-1 (AP-1) and nuclear factor-kappa B (NF-kappa B). The implication of the H1-receptor in these effects is controversial. Diphenhydramine is a first-generation H1-receptor antagonist while mizolastine and desloratadine are second-generation compounds. Mizolastine is also an inhibitor of 5-lipoxygenase (5-LO), an enzyme that has been involved in NF-kappa B activation. Objective We measured the ability of antihistamines to reverse histamine-induced smooth muscle contraction, an effect that involves the H1-receptor. We then investigated whether these drugs affect NF-kappa B and AP-1 activities in A549 lung epithelial cells, and whether this potential regulation involves H1-receptor and 5-LO. Methods Muscle tone was measured on tracheal segments of guinea-pigs. The H1-receptor was overexpressed by transfection and detected by Western blotting and immunofluorescence microscopy. NF-kappa B and AP-1 activities were assessed by reporter gene assays in cells overexpressing or not overexpressing the H1-receptor. Production of regulated upon activation, normal T cell expressed andsecreted (RANTES), a chemokine whose expression is induced through NF-kappa B, was measured using an immunoassay. Results H1-receptor antagonists reversed histamine-induced contraction in a dose-dependent manner. Induction of AP-1 and NF-kappa B activities by histamine and the down-regulatory effect of antihistamines required overexpression of the H1-receptor. In contrast, when tumour necrosis factor-alpha and a phorbol ester were used to stimulate NF-kappa B and AP-1 activities, respectively, repression of these activities did not involve the H1-receptor. Indeed, repression was triggered only by a subset of H1-receptor antagonists and was not stronger after overexpression of the H1-receptor. Mizolastine and desloratadine dose-dependently decreased tumour necrosis factor-alpha-induced production of RANTES. Diphenhydramine, H2- and H3-receptor antagonists as well as selective inhibitors of 5-LO were ineffective in this assay. Conclusion Repression of NF-kappa B and AP-1 activities by H1-receptor antagonists involves H1-receptor-dependent and -independent mechanisms but not 5-LO.
引用
收藏
页码:947 / 956
页数:10
相关论文
共 54 条
  • [11] PHARMACODYNAMIC AND PHARMACOKINETIC STUDIES WITH AZELASTINE IN THE GUINEA-PIG - EVIDENCE FOR PREFERENTIAL DISTRIBUTION INTO THE LUNG
    CHAND, N
    ADUSUMALLI, VE
    NOLAN, K
    DIAMANTIS, W
    WICHMANN, JK
    PIVONKA, J
    LANGEVIN, CN
    WONG, KK
    KUCHARCZYK, N
    SOFIA, RD
    [J]. ALLERGY, 1993, 48 (01) : 19 - 24
  • [12] Plasma and skin suction-blister-fluid pharmacokinetics and time course of the effects of oral mizolastine
    Chosidow, O
    Dubruc, C
    Danjou, P
    Fuseau, E
    Espagne, E
    Bianchetti, G
    Thenot, JP
    Herson, S
    Rosenzweig, P
    Revuz, J
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 50 (04) : 327 - 333
  • [13] CHUNG KF, 1997, ASTHMA, P673
  • [14] The connection between allergic rhinitis and bronchial asthma
    Corren, Jonathan
    [J]. CURRENT OPINION IN PULMONARY MEDICINE, 2007, 13 (01) : 13 - 18
  • [15] Donovan CE, 1999, J IMMUNOL, V163, P6827
  • [16] Alveolar epithelial type II cell: defender of the alveolus revisited
    Fehrenbach, H
    [J]. RESPIRATORY RESEARCH, 2001, 2 (01) : 33 - 52
  • [17] Desloratadine: A new, nonsedating. oral antihistamine
    Geha, RS
    Meltzer, EO
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 107 (04) : 752 - 762
  • [18] Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells
    Genovese, A
    Patella, V
    DeCrescenzo, G
    DePaulis, A
    Spadaro, G
    Marone, G
    [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 1997, 27 (05) : 559 - 567
  • [19] Goldhill J, 1998, ARZNEIMITTEL-FORSCH, V48, P179
  • [20] Grundmann JU, 2001, PHOTOCHEM PHOTOBIOL, V74, P587, DOI 10.1562/0031-8655(2001)074<0587:UERCOM>2.0.CO